Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171032 | 1.00 | HPGD (0.60) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL4171034 | 1.00 | HPGD (0.60) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL3667858 | 0.97 | HPGD (0.59) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL4177716 | 0.95 | HPGD (0.63) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL8018 | 0.93 | HPGD (0.58) | HPGDEPHX1RECQLMAPTKDM4E | |
| Hydrochloric Acid SCHEMBL307023 | 0.91 | HPGD (0.57) | HPGDEPHX1RECQLMAPTKDM4E | |
| Acetic Acid SCHEMBL6198968 | 0.88 | HPGD (0.54) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL376485 | 0.87 | MAPT (0.55) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL181566 | 0.87 | MAPT (0.55) | HPGDEPHX1RECQLMAPTKDM4E | |
| SCHEMBL28357552 | 0.87 | HPGD (0.53) | HPGDEPHX1RECQLMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747243-A1 | LIGANDS AND COMPOSITIONS AND METHODS OF USE THEREOF | Baylor College of Medicine (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| EP-4100394-B1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2025229494-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-11-06 | — | — | WO | disclosed |
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-07 | — | — | US | disclosed |
| US-12331035-B2 | Bicyclic compound and use thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2025-06-17 | — | — | US | disclosed |
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | GILEAD SCIENCES, INC. | 2025-04-10 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | STINGRAY THERAPEUTICS INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-1796793-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007067629-A1 | BRADYKININ 1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| WO-2006029154-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| EP-0888351-B1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | THOMAE GMBH DR K (DE) | 2003-10-15 | — | — | EP | disclosed |
| EP-0888351-A1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-01-07 | — | — | EP | disclosed |
| US-5821240-A | ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS | DR. KARL THOMAE GMBH (DE) | 1998-10-13 | — | — | US | disclosed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115619-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | ZYX, CCNY, NCAPD3 | HPGD 550/4885EPHX1 3298/4885RECQL 378/4885 |
| US-20250250230-A1 | HETEROCYCLIC COMPOUND | HCRTR2, HCRTR1, NPY2R | HPGD 697/4885EPHX1 1023/4885RECQL 3259/4885 |
| US-20070259856-A1 | Method for Activating Trpv4 Channel Receptors by Agonists | TRPV4, TRPV2, TRPV3 | HPGD 758/4885EPHX1 695/4885RECQL 4562/4885 |
| US-12331035-B2 | Bicyclic compound and use thereof | PRMT5, PRMT6, PRMT1 | HPGD 2821/4885EPHX1 3371/4885RECQL 3554/4885 |
| US-20250092018-A1 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | ENPP1, ENPP3, PDE7A | HPGD 440/4885EPHX1 306/4885RECQL 361/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | HPGD 3927/4885EPHX1 4351/4885RECQL 2758/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | HPGD 1474/4885EPHX1 4311/4885RECQL 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.